UroGen Pharma Ltd. announced that Shawn Cline Tomasello has been appointed to its board of directors. Ms. Tomasello is an industry expert who most recently served as chief commercial officer at Kite, a Gilead Company. Ms. Tomasello brings over 30 years of experience in the life sciences industry and most recently served as chief commercial officer of Kite Pharma (subsequently Kite, a Gilead Company), where she led the commercialization of Yescarta (axicabtagene ciloleucel), the first approved chimeric antigen receptor (CAR) T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin lymphoma. Prior to joining Kite, Ms. Tomasello served as chief commercial officer at Pharmacyclics Inc.